



For immediate release, September 9, 2009

Report from the extraordinary general meeting of Genovis AB (publ) September 8, 2009

The extra general meeting of Genovis AB (publ) decided on a new share issue with preferential rights for existing shareholders, at which two existing shares give right to the subscription of one new share at issue price of SEK 1 per share. The decision means that the share capital can be increased with altogether SEK 2 813 293,2 through the issuing of 7 033 233 new shares. Following the completed share issue the share capital will amount to, at the maximum, SEK 8 439 879,6, and the number of shares to 21 099 699. The company receives approx. SEK 7 million before costs for the share issue. The share issue results in a dilution effect of 33%.

Time plan for the share issue

8 September 2009	Last trading day for the Genovis share day to be able to participate in the new share issue.
11 September 2009	Record day for participation in the new share issue, i.e. the shareholders registered in the Genovis shareholder's register as on this day receive subscription rights for the new share issue.
16-30 September 2009	Subscription period. Subscription with preferential rights through cash payment during the subscription period. Intention to subscribe can be made throughout the whole subscription period. There will be no trading in subscription rights.

For more information, contact:
Sarah Fredriksson, CEO, Genovis AB
+46-46-10 12 30
sarah.fredriksson@genovis.com

Genovis is a biotech company on the leading edge of nanotechnology and nanoparticles. The company's patented nano-induced magnetic transfer (NIMT®) technology was developed to facilitate effective preclinical research for the life science industry. Genovis shares are listed on the First North OMX Nordic Exchange. Mangold Fondkommission is our certified advisor and liquidity guarantor.